The role of high sensitivity C-reactive protein in coronary artery disease risk prediction: A review

Journal Medical Libanais

Volumn 52, Issue 1, 2004, Pages 39-47

  Abou Diwan, Charbel H ^a   Oghlakian, Gerard O ^b   Antonios, Samer I ^c   Otrock, Zaher K ^b   Rebeiz, Abdallah G ^b  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CERIVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIAGNOSTIC VALUE; HUMAN; OUTCOMES RESEARCH; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANTILIPEMIC AGENTS; ASPIRIN; C-REACTIVE PROTEIN; CLINICAL TRIALS; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY DISEASE; FEMALE; HUMANS; MALE; NEPHELOMETRY AND TURBIDIMETRY; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 14644424624     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of Factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999; 163: 3957-62.
2. Yu H, Rifai N. High sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem 2000; 33 (8): 601-10.
3. Koenig W, Wanner C. C-reactive protein and coronary artery disease - What is the link? Nephrol Dial Transplant. 1999 Dec; 14 (12): 2798-800.
4. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-9.
5. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45 (12): 2136-41.
6. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52-8.
7. Ledue TB, Weiner DL, Sipe J, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays fro C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann Clin Biochem 1998; 35: 745-53.
8. Meier-Ewart HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001; 47: 426-30.
9. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radio-iodinated human C-reactive protein in health and disease. J Clin Invest 1993; 91: 1351-7.
10. Ridker PM. Clinical association of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
11. Farmer JA, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler Rep 2002; 4: 92-8.
12. Ridker PM, Morrow DA. C-reactive protein inflammation, and coronary risk. Cardiol Clin 2003 Aug; 21 (3): 315-25.
13. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 2: 115-26.
14. Zebrack JS, Anderson JL. The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease. Curr Cardiol Rep 2002; 4 (4): 278-88.
15. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement in components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.
16. Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima : role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20 (9): 2094-9.
17. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. PNAS 2002; 99 (20): 13043-8.
18. Siegl J, Rent R, Gewürz H. Interaction of C-reactive protein with the complement system. J Exp Med 1974; 140: 631-7.
19. Wolbrink GJ, Brouwer MC, Buysmann S, Ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo. J Immunol 1996; 157: 473-9.
20. Torzewski J, Torzewski M, Bowyer DE et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Atherioscler Thromb Vasc Biol 1998; 18: 1386-92.
21. De Ferranti S, Rifai N. C-reactive protein and cardiovascular disease : a review of risk prediction and interventions. Clinica Chimica Acta 2002; 317: 1-15.
22. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76: 69C-77C.
23. Rubins HB, Robins SJ, Collins D et al. Distribution of lipids in 8500 men with coronary artery disease. Am J Cardiol 1995; 75: 1196-201.
24. Euroaspire Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82.
25. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999; 130: 933-7.
26. Abrams J. C-reactive protein, inflammation, and coronary risk: an update. Cardiol Clin 2003 Aug; 21 (3): 327-31.
27. Ridker PM. High sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-18.
28. Koenig W, Pepys MB. C-reactive protein risk prediction: low specificity, high sensitivity. Ann Intern Med 2002; 136: 550-2.
29. Yeh ETH, Willerson JT. Coming of age of C-reactive protein. Using inflammation markers in cardiology. Circulation 2003; 107: 370-2.
30. Wilkins J, Gallimore RJ, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassays of C-reactive protein. Clin Chem 1998; 44: 1358-61.
31. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996; 144: 437-47.
32. Albert MA, Ridker PM. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1999; 1: 99-104.
33. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of Interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
34. Tracy RP, Psaty BM, Macy E et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2167-76.
35. Tracy RP, Lemaitre RN, Psaty BM et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.
36. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem. 2004 Mar; 50 (3): 574-81.
37. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
38. Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation 1999; 99: 237-42.
39. Clearfield M, Whitney EJ, Weis S et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS): baseline characteristics and comparison with USA population. J Cardiovasc Risk 2000 Apr; 7 (2): 125-33.
40. Folsom AR, Aleksic N, Catellier D, Juneja HS, WU KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002; 144: 233-8.
41. Roivainen M, Viik-Kajander M, Palosuo T et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000; 101: 252-7.
42. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of C-reactive protein, serum amyloid-A and fibrinogen with prevalent coronary heart disease - baseline findings of the PAIS project. Atherosclerosis 2001; 156: 451-6.
43. Standberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000; 20: 1057-60.
44. Folsom AR, Pankow JS, Tracy RP et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112-17.
45. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55: 445-51.
46. Jager A, Van Hinsenbergh VWM, Kostense PJ et al. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-8.
47. Aronson D, Bartha P, Zinder O et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 2004 Jan; 21 (1): 39-44.
48. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5.
49. Chambers JC, Eda S, Basset P et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104: 145-50.
50. Yamada S, Gotoh T, Nakashima Y et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population. Am J Epidemiol 2001; 153: 1183-90.
51. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease : prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
52. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
53. Rifai N, Ridker PM. High sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47 (3): 403-11.
54. Ridker PM, Hennekens CH, Rifai N, Burning JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-16.
55. Hulley S, Grady D, Bush T et al. Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 80: 605-13.
56. Cushman M, Legault C. Barret-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-22.
57. Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001; 153: 1094-101.
58. Vehkavaara S, Silvelra A, Hakal-Ala-Pietila T et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25.
59. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-8.
60. Bulow B, Hagmar L, Mikoczy Z, Nordtrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997; 357: 425-31.
61. Sesmilo G, Miller KK, Hayden D, Klibanski A. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86: 5774-81.
62. Sesmilo G, Biller BM, Llevadot J et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133: 111-22.
63. Manson JE, Tosteson H, Ridker PM et al. Current concepts: primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406-16.
64. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
65. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
66. Haidari M, Javadi E, Sadeghi B, Hajilooi M, Ghanbili J. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem 2001; 33: 309-15.
67. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high sensitivity C-reactive protein and lipid screening. Clin Chem 2001; 47 (1): 28-30.
68. Ridker PM, Cushman M, Stampfer MJ, Tracy RP. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
69. Azar RR, Klayme S, Germanos M et al. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol 2003; 92: 236-9.
70. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002; 40: 49-55.
71. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
72. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98 (9): 839-44.
73. Kleemann R, Verschuren L, De Rooij BJ et al. Evidence for anti-inflammatory activity of statins and PPAR {alpha}-activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103: 4188-94.
74. Ridker PM, Rifai N, Clearfiled M et al. Measurement of C-reactive protein for the targeting statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
75. Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 2003 Oct; 26 (10): 472-6.
76. Jialal I, Stein D, Balis D, Grundy SM, Devaraj S. Effect of HMG-CoA reductase inhibitors therapy on high sensitivity C-reactive protein levels. Circulation 2001; 103: 1933-5.
77. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3.
78. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
79. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in non-diabetic patients with the metabolic syndrome. Am J Cardiol 2004 Feb 1; 93 (3): 362-5.
80. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003 Nov 19; 42 (10): 1757-63.
81. Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. Am J Cardiol 2004 Jan 15; 93 (2): 221-5.
82. Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother Jan 2004; 38: 110-18.
83. Pearson TA, Mensah GA, Wayne Alexander R et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the centres for disease control and prevention and the American heart association. Circulation 2003; 107: 499-511.